Article 229-C of the Brazilian IP Law on the ANVISA's prior consent for pharmaceutical products or processes patents in Brazil, has been revoked.
This article would generate a duplicity in the analysis on patentability requirements, and had cause intense debate due to the delays caused in the substantive examination at INPI.
Would you like to read more about the revocation of Article 229-C of the Brazilian IP Law?
To read more, please refer to the Ungria's website.
- Publication date
- 13 October 2021